Remove 2025 Remove Hemorrhage Remove Thrombolysis
article thumbnail

Abstract DP4: When Does Clinical Worsening Begin in Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis?

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ADP4-ADP4, February 1, 2025. Introduction:Intravenous thrombolysis with alteplase (tPA) or tenecteplase (TNK) is a first-line treatment for acute ischemic stroke. The most serious risk associated with IV thrombolytics is symptomatic intracranial hemorrhage (sICH).

article thumbnail

Abstract TP8: Prolonged Low-Dose Intravenous Thrombolysis in early recurrent Stroke: ESR-PROLONG Study

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP8-ATP8, February 1, 2025. The safety of the treatment was evaluated based on the occurrence of any complications, the occurrence of intracerebral hemorrhage, and the occurrence of symptomatic intracerebral hemorrhage (assessed according to SITS-MOST criteria).Results:44

article thumbnail

Abstract WP1: Intravenous Thrombolysis for Central Retinal Artery Occlusion in Routine Clinical Practice

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page AWP1-AWP1, February 1, 2025. One of the considered and currently increasingly preferred options is intravenous thrombolysis. Overall, intracerebral hemorrhage occurred in 6.3%. According to our data, intravenous thrombolysis is also an effective and safe therapy here.

article thumbnail

Abstract TP25: Benefits and Risks of Antiplatelet Versus Thrombolysis for Mild Acute Ischemic Stroke: Update of a Living Systematic Review and Meta-analysis

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP25-ATP25, February 1, 2025. Background:Previous study found that compared with thrombolysis, antiplatelet did not improve outcomes but reduce the risk of symptomatic intracranial hemorrhage(sICH) for mild acute ischemic stroke(AIS) defined as National Institutes of Health Stroke Scale score 0 to 5.

article thumbnail

Abstract WP11: Efficacy and Safety Outcomes of thrombolysis for stroke in Low- and Middle-Income countries: Systematic Review and Metanalysis

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page AWP11-AWP11, February 1, 2025. Introduction:Stroke is a leading cause of disability and mortality worldwide, with thrombolysis as a critical treatment. Studies aiming to assess the outcomes of thrombolysis after ischemic stroke in LMIC were selected.

article thumbnail

Abstract DP1: Intravenous thrombolysis for acute ischemic stroke patients with cerebral amyloid angiopathy

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ADP1-ADP1, February 1, 2025. Background:Cerebral amyloid angiopathy (CAA) is a hemorrhagic cerebrovascular disease that is thought to be due to excess protein deposition in vessel walls that lead to fragility and increase the risk of rupture. to 5.75], p<0.001), and SAH (aOR 2.42 [95%CI 1.41-4.16],

article thumbnail

Abstract DP3: Thrombolysis for Ischemic Stroke after 4.5 hours without thrombectomy: A Meta-analysis of Randomized Controlled Trials

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ADP3-ADP3, February 1, 2025. hour window, and reperfusion through thrombolysis has been shown to enhance functional outcomes in patients with salvageable brain tissue beyond this timeframe.Objective:The aim of this study is to assess the efficacy and safety of thrombolysis administered more than 4.5